OncoMed Forced to Regroup After Celgene-Partnered Drug Fails for a Second Time
By Heather Cartwright
Pharma Deals Review: Vol 2017 Issue 5 (Table of Contents)
Published: 25 May-2017
DOI: 10.3833/pdr.v2017.i5.2248 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
OncoMed Pharmaceuticals and its once-promising cancer stem cell technology has had a torrid time of late, with Bayer Pharma declining to exercise options on two Phase I Wnt pathway inhibitors and a trio of clinical trial failures jeopardising the future of its two other major collaborations...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS